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Background. The aim of the present study was to examine sources of variation for serum cystatin C in a healthy Greek population.
Methods. Cystatin C together with basic clinical chemistry tests was measured in a total of 490 adults (46 ± 16yrs, 40% males)
who underwent an annual health check. Demographic, anthropometric, and lifestyle characteristics were recorded. Results. Higher
values of cystatin C were observed among males (P = .04), participants aged over 65 years (P<. 001), current smokers (P = .001)
and overweight/obese participants (P = .03). On the contrary, alcohol consumption and physical activity seemed to have no
inﬂuence on cystatin C levels (P = .61; P = .95, resp.). Conclusions. In interpreting serum cystatin C values in a healthy adult
population, age, gender, Body Mass Index, and cigarette smoking need to be considered, and determination of reference ranges
among distinct subpopulations seem to be prudent.
1.Introduction
Cystatin C is a nonglycosylated, low molecular weight
(13.250Da), basic protein that is a member of the cystatin
superfamily of cysteine protease inhibitors [1–3]. It consists
of 120 amino acids, it is produced by all nucleated cells at
a constant rate, and it is excreted by the kidneys by free
glomerular ﬁltration and complete tubular reabsorption and
degradation [4–6]. Therefore, serum concentration levels of
cystatin C are almost totally dependent on the glomerular
ﬁltration rate and—unlike serum creatinine levels which
increase after glomerular ﬁltration rate has fallen by approxi-
mately 50%—even a slight reduction in glomerular ﬁltration
rate causes a rise in serum cystatin C [7, 8]. Besides its
usefulness as a marker of renal function, serum cystatin
C appears to be a prognostic marker of cardiovascular
events and death among elderly persons without chronic
kidney disease [9, 10]. Therefore, it is important to establish
reference values of cystatin C not only for nephrologists, but
for cardiologists as well.
In this study, serum cystatin C concentrations were
measured in a healthy Greek adult population, and reference
intervals were derived after taking under consideration
sources of variation for this population.
2.MaterialsandMethods
2.1. Participants. Between April 2009 and January 2010, a
total of 490 consecutive adults (85% participation rate),
who had visited the “Polykliniki” General Hospital for an
annual health check, agreed to participate in the study. The
retrieved data were conﬁdential, and the study followed
the ethical considerations provided by the World Medical
Association (52nd WMA General Assembly, Edinburgh,
Scotland, October 2000). Moreover, the Institutional Review2 Cardiology Research and Practice
Board approved the design, procedures, and aims of the
study (GA 23/14.05.2009). All participants were informed
about the procedures of the study and agreed to participate
providing written informed consent.
Subjects who reported chronic diseases such as renal
failure, diabetes mellitus, cardiovascular diseases, cancer,
thyroid dysfunctions, or pregnancy were excluded as well as
those treated with drugs that may inﬂuence renal function or
cystatin C concentrations (i.e., antihypertensives, diuretics,
antiinﬂammatory agents, hypoglycemic agents, anticonvul-
sants, and antibiotics). Other exclusion criteria were: (1)
fasting serum glucose ≥ 126mg/dL, (2) systolic blood pres-
sure ≥ 140mmHg or diastolic blood pressure ≥ 90mmHg,
(3) Body Mass Index (BMI) ≤ 18.5o r≥ 30, to avoid the
extremes of body size, and (4) eGFR (glomerular ﬁltration
rate) < 60/ml/min/1.73m2, a threshold deﬁning Chronic
Kidney Disease (CKD) by the independent international
Kidney Disease Improving Global Outcomes Organization
(KDIGO) using the simpliﬁed Modiﬁcation of Diet in Renal
Disease Study (MDRD) equation [11, 12]. Therefore, 279
individuals (40 ± 13 yrs, 37% males) fulﬁlled the above-
mentioned criteria and were found eligible to participate in
the study.
2.2. Other Characteristics. Participants were classiﬁed to the
following age categories: 18–44yrs, 45–64yrs, and ≥65yrs.
Waist circumference and height (without shoes) were mea-
sured to the nearest 0.5cm, and weight was measured with
a lever balance, to the nearest 100g, without shoes, in
light undergarments. Body Mass Index (BMI) was then
calculated as weight in kilograms divided by the square of
standing height in meters. Participants were then classiﬁed
in those with normal values of BMI (i.e., <25kg/m2)a n dt o
overweight/obese(BMI ≥25kg/m2).Withrespecttolifestyle
characteristics, participants were asked to ﬁll in a 10-grade
scale range regarding their physical activity status (grade of
scale used: 1–10, where 1 denotes sedentary lifestyle and 10
daily hard activity of at least 30 minutes). Participants with
score ≤6 were classiﬁed as with low/moderate activity, while
those with score >6 were considered as highly active. Alcohol
consumption was assessed as the self-reported number
of drinks per week and participants were categorized as
never/rare (i.e., 0-1 drink/week) and current drinkers (i.e.,
>1drink/week). Currentcigarettesmoking (yes,no)wasalso
recorded.
2.3. Biochemical Characteristics. Systolic and diastolic blood
pressures, together with fasting serum glucose, serum cre-
atinine, and cystatin C, were measured in all participants.
Blood pressure was measured by the same physician using
a standard mercury sphygmomanometer on the right arm
of the seated subject. Venipuncture was performed for each
participant, early in the morning (between 07:00am and
11:00am), after a 12-hour fasting period by applying a
natural latex rubber strap and using a 20mL syringe. Blood
was immediately transferred to two tubes without anticoag-
ulant (Greiner Vacuette, Cat. no. 455071). Samples were left
undisturbed for 20 minutes to clot and then centrifuged at
4000 Rotations per Minute (Relative Centrifugal Force: RCF
2.7) for 10 minutes so as to obtain serum.
2.4. Laboratory Analyses. Glucose was determined via an
enzymatic colorimetric test (glucose oxidase PAP, Trinder
endpoint reaction, GOD-PAP). Serum creatinine was deter-
mined via a kinetic colorimetric assay based on the reaction
ofcreatinine with picric acid inalkaline solution and cystatin
Cviaaparticle-enhancedimmunoturbidimetric assay.Inthe
latter case, human cystatin C agglutinates with latex particles
coated with anticystatin C antibodies, and the aggregate is
determined turbidimetrically at 546nm.
Reproducibility in the lab has been determined using
h u m a ns a m p l e sa n dc o n t r o l si na ni n t e r n a lp r o t o c o l .F o r
the above mentioned tests, within run and between day,
coeﬃcients of variation (CV) were less than 8%. Two levels
of control sera were used for these assays (Precinorm U plus
12149435122 & Precipath U plus 12149443122 for glucose
and serum creatinine, cystatin C control set 04975936190
for cystatin C). Control recovery for all tests was very close
to the recommended target values (TV ± 5%). Accuracy
of results is further supported by participation in suitable
external quality assurance program for glucose and serum
creatinine (ESEAP). All measurements were performed on
a Roche/Modular Analytics analyzer. Reagents, calibrators,
controls, and consumables were purchased from same sup-
plier (Roche Diagnostics GmbH, Sandhofer Straße 116, D-
68305 Mannheim, Germany).
2.5. Statistical Analysis. Continuous variables are presented
as mean ± standard deviation and categorical variables as
absolute (N) and relative frequencies (%). Comparisons
of continuous variables between groups of study were
performed using the independent samples t-test and the
Analysis of Variance, after controlling for the normality of
the distribution. Associations between categorical variables
were tested using the chi-square test. Distribution of cystatin
C levels was presented for the 2.5th, 5th, 10th, 25th, 50th
(median), 75th, 90th, 95th, and 97.5th percentile. Subgroups
analyses were performed by gender, age category (i.e., 18–44,
45–64, and ≥65 years old), obesity status (< or ≥25kg/m2),
currentsmoking(yesversusno),alcoholdrinking(yesversus
no), and physical activity status (low/moderate versus high).
AllstatisticalanalyseswereperformedusingtheSPSSversion
14 (SPSS Inc., Chicago, Il, USA).
3. Results and Discussion
3.1. Descriptive Characteristics. Thirty-seven percent of par-
ticipants were male, while the mean age between genders
did not diﬀer (40 ± 14 for males, 40 ± 13 for females,
P = .81). Diﬀerences were not observed as well in physical
activitystatusbetweengenders(i.e.,5.8±2.1formalesversus
5.9±2.3 for females, P = .91). Percentage of current smokers
was similar between males (34%) and females (36%) (P =
.79). Approximately 2/3 of males and 27% of females were
considered as overweight/obese (P<. 001), while 85% of
males and 73% of females were current drinkers (P = .02).Cardiology Research and Practice 3
Table 1: The distribution of serum cystatin C levels according to gender (i.e., males and females) and age groups, of apparently healthy
participants in the study.
Males Females
18–44 45–64 ≥65 Total 18–44 45–64 ≥ 65 Total
Percentiles of
cystatin C
Minimum 0.50 0.52 0.83 0.50 0.52 0.61 0.74 0.52
2.5 0.56 0.52 0.83 0.56 0.54 0.61 0.74 0.57
5 0.63 0.59 0.83 0.64 0.60 0.63 0.74 0.61
10 0.66 0.70 0.83 0.67 0.62 0.64 0.74 0.64
25 0.71 0.73 0.89 0.72 0.69 0.71 0.87 0.70
50 0.77 0.82 0.98 0.80 0.76 0.79 0.99 0.78
75 0.87 0.93 1.07 0.90 0.82 0.89 1.04 0.84
90 0.93 1.00 — 0.99 0.88 1.00 — 0.96
95 1.00 1.14 — 1.07 1.01 1.07 — 1.01
97.5 1.08 — — 1.13 1.03 1.12 — 1.07
Maximum 1.10 1.21 1.18 1.21 1.05 1.12 1.14 1.14
Table 2: The distribution of cystatin C levels according to obesity and smoking status, of apparently healthy participants in the study.
Overweight/obesity Current smoking
No Yes No Yes
Percentiles of cystatin C
Minimum 0.52 0.50 0.50 0.52
2.5 0.57 0.60 0.56 0.59
5 0.61 0.63 0.61 0.64
10 0.64 0.68 0.64 0.68
25 0.70 0.72 0.70 0.74
50 0.77 0.80 0.76 0.81
75 0.84 0.90 0.84 0.92
90 0.95 0.99 0.94 1.01
95 1.02 1.04 1.00 1.06
97.5 1.07 1.15 1.08 1.11
Maximum 1.12 1.21 1.21 1.18
3.2. Distribution of Cystatin C Levels. Cystatin C levels varied
from 0.50 to 1.21mg/L among males and from 0.52 to
1.14mg/L among females. In addition, cystatin C levels were
normally distributed among the 176 healthy women and
103 healthy men that comprised the studied population
(Figure 1).
The distribution of cystatin C levels among age groups
between the two genders is presented in Table 1. In general,
higher levels were observed for males as compared to females
in all age groups. Speciﬁcally, cystatin C varied from 0.50
to 1.10mg/L among males aged 18–44yrs, from 0.52 to
1.21mg/L among males aged 45–64yrs, and from 0.83 to
1.18mg/L among males over 65yrs. Among females, the cys-
tatin C levels varied from 0.52 to 1.05, 0.61 to 1.12, and 0.74
to 1.14mg/L, respectively, for each age group (Table 1). The
distribution of cystatin C levels was furthermore examined
according to obesity and current smoking status. Levels of
cystatin C varied from 0.52 to 1.12mg/L for participants
with BMI < 25kg/m2 and from 0.50 to 1.21mg/L for
overweight/obese participants. Moreover, cystatin C levels
varied from 0.50 to 1.21mg/L for never or ex-smokers
and from 0.52 to 1.18mg/L for current smokers (Table 2).
Regarding the distribution of cystatin C levels according to
physical activity status, this varied from 0.50 to 1.18mg/L
among participants with low physical activity and from 0.52
to 1.21mg/L among highly active participants. In addition,
cystatin C levels varied from 0.52 to 1.10mg/L among
never/rare drinkers and from 0.50 to 1.21mg/L among
drinkers (data not shown here).
Diﬀerences in mean values of cystatin C levels were
observed between genders, age group, smoking, and obesity
status. In particular, higher values were noticed among
males (P = .04), older participants aged over 65yrs (P<
.001), current smokers (P<. 001), and overweight/obese
participants (P = .03). In contrast, cystatin C levels
did not seem to diﬀer regarding alcohol drinking status
and physical activity status (P = .61, P = .95, resp.)
(Table 3).4 Cardiology Research and Practice
Table 3: Mean values and standard deviation of serum cystatin C
levels among subgroups of apparently healthy participants in the
study.
Cystatin C (mg/L) P
Gender .04
Male 0.82 ± 0.13
Female 0.79 ± 0.12
Age group <.001
18–44 0.77 ± 0.11
45–64 0.82 ± 0.13
≥65 0.98 ± 0.12
Overweight/obesity .03
No 0.78 ± 0.12
Yes 0.82 ± 0.13
Current smoking .001
No 0.78 ± 0.12
Yes 0.82 ± 0.13
Alcohol drinking .61
0-1 drinks/week 0.80 ± 0.13
>1 drinks/week 0.79 ± 0.13
Physical activity .95
Never/rare 0.80 ± 0.12
High activity 0.80 ± 0.13
Various physiological sources of variation for serum
cystatin C such as age, gender, BMI, cigarette smoking, and
alcohol consumption have been reported based on analysis
of healthy adult populations. Most studies have shown age-
related diﬀerences in serum cystatin C, demonstrating that
its levels increase with age [13–17]. Indeed, recent studies
deﬁne reference values separately for adults and for older
individuals. These studies have documented a variation in
cystatin C levels as a function of age, probably due to the
physiological aging of renal function [18–20]. In this study,
higher values were noticed among older participants aged
over 65 yrs (P<. 001).
Gender diﬀerences in cystatin C levels have not been
consistently observed. Such diﬀerences were signiﬁcant in
some studies, especially for adults below 60 years of age [20–
22], but not signiﬁcant in others [13, 23]. In this study,
gender diﬀerences in cystatin C were revealed, with higher
values of cystatin C among males as compared with females.
The ﬁndings of this study, regarding the inﬂuence of
smoking in the levels of cystatin C, have been also conﬁrmed
by other studies [13, 24]. It seems likely that smoking is an
independent source of variation for cystatin C, although the
mechanism is not known.
Previous studies with respect to positive association of
cystatin C levels with BMI support the above mentioned
results of this study [25, 26]. Speciﬁcally, higher values
of cystatin C levels among overweight/obese individuals in
comparison with normal weight individuals were revealed.
Laboratory studies have examined the expression of cathep-
sin S as a new biomarker of adiposity and have shown that
human adipose tissue secretes and expresses cathepsin S,
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Figure 1: The gender-speciﬁc distribution of serum cystatin C
levels among healthy participants of the study.
which is upregulated in obesity [27]. Cystatin C regulates
cathepsin S activity by acting as an endogenous inhibitor.
It has been found that cystatin C secretion increased and
cathepsin S decreased during preadipocyte diﬀerentiation,
suggesting a possible role of cystatin C in adipogenesis [28].
Alcohol consumption and physical activity did not seem
to inﬂuence cystatin C levels in the studied population. This
is in accordance with most studies that have been conducted
until today [13, 29, 30].
As it is clearly mentioned on the package insert of the
commercial assay for cystatin C “Each laboratory should
investigate the transferability of the expected values to its
own patient population and if necessary determine its own
reference ranges.”
4. Conclusions
This is—to the best of our knowledge—the ﬁrst study
for determination of cystatin C reference values in Greek
population. In the era of newly discovered properties and
clinical signiﬁcance of cystatin C, factors such as age, gender,
BMI, and cigarette smoking need to be considered when
interpreting serum cystatin C values even in a carefully
selected healthy adult population. Determination of refer-
ence ranges among distinct subpopulations must be taken
into consideration.
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